methyl 2-hydroxyimino-2-(pyridyl-2')acetate | 154410-82-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: methyl 2-hydroxyimino-2-(pyridyl-2')acetate
• 英文别名: methyl 2-(N-hydroxyimino)-2-(pyridin-2-yl)acetate；methyl 2-(hydroxyimino)-2-(pyridin-2-yl)acetate；hydroxyimino-[2]pyridyl-acetic acid methyl ester；Hydroxyimino-[2]pyridyl-essigsaeure-methylester；hydroxyimino-pyridin-2-yl-acetic acid methyl ester；methyl 2-hydroxyimino-2-pyridin-2-ylacetate
• CAS: 154410-82-9
• 化学式: C₈H₈N₂O₃
• 分子量: 180.163
• InChiKey: INGNGFMBSDVQRV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  71.8
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  methyl 2-hydroxyimino-2-(pyridyl-2')acetate 在 钯 、 氢气 、 二氯甲烷 作用下， 以 乙醇 为溶剂， 反应 16.0h， 以to give Amino-pyridin-2-yl-acetic acid methyl ester (1.8 g) as a yellow oil which的产率得到2-氨基-2-(吡啶-2-基)乙酸甲酯
  参考文献：
  名称：

  DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-alpha]IMIDAZOLE-3-CARBOXYLIC ACID AMIDES

  摘要：

  6,7-二氢-5H-咪唑[1,2-α]咪唑-3-羧酸酰胺的衍生物表现出良好的抑制CAMs和白细胞整合素相互作用的效果，因此在治疗炎症性疾病方面具有用处。

  公开号：

  US20110224188A1
• 作为产物：
  描述：

  2-propionyloxypyridine 在 溶剂黄146 、 sodium nitrite 作用下， 以 水 为溶剂， 反应 2.0h， 以92%的产率得到methyl 2-hydroxyimino-2-(pyridyl-2')acetate
  参考文献：
  名称：

  天然除草剂MBH-001及其类似物的全合成

  摘要：

  环硝酮是关键：开发了一种天然除草剂MBH-001的灵活途径。与氮杂内酯相反，使用相应的硝酮可确保阴离子与醛类的醛醇型反应中的区域化学反应（2位对4位）。这项工作还导致测定了MBH-001的相对和绝对立体化学。

  DOI：

  10.1002/ejoc.202000294

文献信息

• Heterocyclic amino acids as synthons. Reactions with dicarbonyl compounds
  作者：Patrik Kolar、Miha Tišler

  DOI：10.1002/jhet.5570300514

  日期：1993.10

  From some alkyl heteroarylglycinates and dicarbonyl compounds various heterocyclic systems are easily accessible. Transformations are described which lead to imidazo[1,5-α]pyridines, heteroaryl-substituted pyrroles, pyrido[1,2-α]pyrazines, pyrido[1,2-α]pyrimidines or quinolizin-4-ones.

  从一些烷基杂芳基甘氨酸盐和二羰基化合物可以容易地获得各种杂环系统。描述了导致咪唑并[1,5-α]吡啶，杂芳基取代的吡咯，吡啶并[1,2-α]吡嗪，吡啶并[1,2-α]嘧啶或喹唑嗪-4-酮的转化。
• PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AS CB1 RECEPTOR ANTAGONIST
  申请人：Tanimoto Koichi

  公开号：US20090258867A1

  公开（公告）日：2009-10-15

  The present invention provides a pyrazolo[1,5-a]pyrimidine compound, having CB1 receptor-antagonizing activity, of the following formula [I]: in which R 1 and R 2 are the same or different and each an optionally substituted aryl group etc, R 0 is hydrogen atom, an alkyl group etc, E is a group of the formula: —C(═O)— or —SO 2 —, R is a group of the following formula [i], [ii] or [iii] etc: Ring A is (a) a C 3-8 cycloalkyl group optionally fused to a benzene ring or (b) a benzene ring, Q is a single bond or a methylene group, Ring B is a 4- to 7-membered aliphatic heterocyclic group, said cyclic group binding via its ring-carbon atom to the adjacent nitrogen atom, X is sulfur atom etc, R 3 is an alkyl group optionally substituted by an alkylthio group, R 4 is hydrogen atom, an alkyl group etc, one of R A and R B is an alkyl group etc, and the other is hydrogen atom, an alkyl group etc, or a pharmaceutically acceptable salt thereof.

  本发明提供了一种具有CB1受体拮抗活性的吡唑并[1,5-a]嘧啶化合物，其化学式[I]如下：其中，R1和R2相同或不同，分别是可选取代的芳基等；R0是氢原子，烷基等；E是以下式子的基团：—C(═O)—或—SO2—；R是以下式子[i]、[ii]或[iii]等的基团：环A是(a)一个C3-8环烷基，可选地融合到苯环上，或(b)一个苯环；Q是单键或亚甲基基团；环B是一个4-7个成员的脂肪族杂环基团，该环基团通过其环碳原子与相邻的氮原子结合；X是硫原子等；R3是可选取代的烷基，可以是烷基硫基等；R4是氢原子，烷基等；RA和RB中的一个是烷基等，另一个是氢原子，烷基等，或其药学上可接受的盐。
• Pyrazolo[1,5-A] pyrimidine compounds as CB1 receptor antagonist
  申请人：Mitsubishi Tanabe Pharma Corporation

  公开号：US08163759B2

  公开（公告）日：2012-04-24

  The present invention provides a pyrazolo[1,5-a]pyrimidine compound, having CB1 receptor-antagonizing activity, of the following formula [I]: in which R1 and R2 are the same or different and each an optionally substituted aryl group etc, R0 is hydrogen atom, an alkyl group etc, E is a group of the formula: —C(═O)— or —SO2—, R is a group of the following formula [i], [ii]or [iii] etc: Ring A is (a) a C3-8 cycloalkyl group optionally fused to a benzene ring or (b) a benzene ring, Q is a single bond or a methylene group, Ring B is a 4- to 7-membered aliphatic heterocyclic group, said cyclic group binding via its ring-carbon atom to the adjacent nitrogen atom, X is sulfur atom etc, R3 is an alkyl group optionally substituted by an alkylthio group, R4 is hydrogen atom, an alkyl group etc, one of RA and RB is an alkyl group etc, and the other is hydrogen atom, an alkyl group etc, or a pharmaceutically acceptable salt thereof.

  本发明提供了一种具有CB1受体拮抗活性的吡唑并[1,5-a]嘧啶化合物，其化学式[I]如下：其中，R1和R2相同或不同，分别为可选择取代的芳基基团等，R0为氢原子、烷基基团等，E为下式的基团：—C(═O)—或—SO2—，R为下式的基团[i]、[ii]或[ iii]等：环A为(a)一个C3-8环烷基团，可选择与苯环融合，或(b)一个苯环，Q为单键或亚甲基基团，环B为一个4-至7-成员的脂环杂环基团，所述环基团通过其环碳原子与相邻的氮原子结合，X为硫原子等，R3为可选择取代的烷基基团，其中该烷基基团被烷基硫基取代，R4为氢原子、烷基基团等，RA和RB中的一个为烷基基团等，另一个为氢原子、烷基基团等，或其药学上可接受的盐。
• Derivatives of 6,7-dihydro-5H-imidazo[1,2-alpha]imidazole-3-carboxylic acid amides
  申请人：Barbosa, Jr. Antonio Jose del Moral

  公开号：US08552205B2

  公开（公告）日：2013-10-08

  Derivatives of 6,7-dihydro-5H-imidazo[1,2-α]imidazole-3-carboxylic acid amide exhibit good inhibitory effect upon the interaction of CAMs and Leukointegrins and are thus useful in the treatment of inflammatory disease.

  6,7-二氢-5H-咪唑[1,2-α]咪唑-3-羧酸酰胺的衍生物表现出良好的抑制细胞黏附分子和白细胞整合素相互作用的效果，因此在治疗炎症性疾病方面具有用途。
• Pyrazolo[1,5-a] pyrimidine compounds as CB1 receptor antagonist
  申请人：Tanimoto Koichi

  公开号：US08921380B2

  公开（公告）日：2014-12-30

  Pyrazolo[1,5-a]pyrimidine compound, having CB1 receptor-antagonizing activity, of formula [I]: wherein R1 and R2 are the same or different and each is an optionally substituted aryl group, etc., R0 is hydrogen, an alkyl group, etc., E is —C(═O)— or —SO2—, R is a group of formula [i], [ii] or [iii], etc: Ring A is a C3-8 cycloalkyl group optionally fused to a benzene ring or a benzene ring, Q is a single bond or a methylene group, Ring B is a 4- to 7-membered aliphatic heterocyclic group, said cyclic group binding via its ring-carbon atom to the adjacent nitrogen atom, X is sulfur atom, etc., R3 is an alkyl group optionally substituted by an alkylthio group, R4 is hydrogen atom, an alkyl group, etc., one of RA and RB is an alkyl group, etc., and the other is hydrogen, an alkyl group, etc., or a pharmaceutically acceptable salt thereof.

  一种具有CB1受体拮抗活性的吡唑并[1,5-a]嘧啶化合物，其化学式为[I]：其中R1和R2相同或不同，每个都是可选择性取代的芳基基团等，R0是氢，烷基基团等，E是—C（═O）—或—SO2—，R是化学式[i]，[ii]或[ iii]等的基团：环A是可选择性融合到苯环或苯环的C3-8环烷基团，Q是单键或亚甲基基团，环B是4-至7-成员的脂肪环异杂环基团，所述环基团通过其环碳原子与相邻的氮原子结合，X是硫原子等，R3是可选择性取代的烷基基团，R4是氢原子，烷基基团等，RA和RB中的一个是烷基基团等，另一个是氢，烷基基团等，或其药学上可接受的盐。